APA (7th ed.) Citation

Tremblay G, Dolph M, Bhor M, Said Q, Elliott B, & Briggs A. (2018). Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia. Dove Medical Press.

Chicago Style (17th ed.) Citation

Tremblay G, Dolph M, Bhor M, Said Q, Elliott B, and Briggs A. Cost-consequence Model Comparing Eltrombopag Versus Romiplostim for Adult Patients with Chronic Immune Thrombocytopenia. Dove Medical Press, 2018.

MLA (9th ed.) Citation

Tremblay G, et al. Cost-consequence Model Comparing Eltrombopag Versus Romiplostim for Adult Patients with Chronic Immune Thrombocytopenia. Dove Medical Press, 2018.